The most common primary disease involved was rheumatoid arthritis (31.86%), followed by psoriasis (20.35%) and Crohn’s disease (19.47%) (Figure 2); however, a variety of other autoimmune conditions were also the causes for TNF-α inhibitor administration. Here, TNF is linked to psoriasis.